Profile for Australia Patent: 2013314442

US Patent Family Members and Approved Drugs for Australia Patent: 2013314442

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,016,504	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
10,918,723	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
12,083,179	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
8,999,313	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
9,326,969	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate
9,707,297	Sep 10, 2033	Salix	PLENVU	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate

Analysis of Scope, Claims, and Patent Landscape for Australian Drug Patent AU2013314442

Last updated: April 22, 2025

Overview of Patent AU2013314442

AU2013314442 is part of a global patent family protecting colon cleansing compositions containing polyethylene glycol (PEG) and ascorbate derivatives. The patent, owned by Norgine BV, claims formulations optimized for bowel preparation, with specific ratios of ascorbic acid, ascorbate salts, and PEG to enhance efficacy and tolerability[1][4][18]. The invention addresses challenges in achieving rapid bowel cleansing without adverse effects such as electrolyte imbalances or oxidative stress[1][18].

---

Key Aspects of Patent Scope and Claims

1. Claim Structure and Compositional Limits

The independent claims define:

• Component (a): 300–800 mmol/L ascorbate anion derived from a mixture of ascorbic acid and ascorbate salts in a molar ratio of 1:4.5 to 1:7.0.
• Component (b): 10–200 g/L PEG[1][4][18].

These ranges are critical for maintaining

References

1. https://pubchem.ncbi.nlm.nih.gov/patent/US10918723
2. https://en.patentfield.com
3. https://www.fbrice.com.au/ip-news-insights/federal_court_invalidates_novartis_patent_term_extension_for_entresto/
4. https://pubchem.ncbi.nlm.nih.gov/patent/KR-101771586-B1
5. https://researchers.mq.edu.au/en/publications/identifying-and-preventing-biopiracy-in-australia-patent-landscap
6. http://manuals.ipaustralia.gov.au/patent/5.6.7.3-support-for-the-claims
7. https://www.fpapatents.com/news-insights/insights/how-appealing-was-2022-some-key-australian-patent-law-cases-of-2022/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4588131/
9. https://search.ipaustralia.gov.au/trademarks/search/quick
10. https://confluence.wipo.int/confluence/pages/viewpage.action?pageId=1072431105
11. https://pharsight.greyb.com/drug/ojemda-patent-expiration
12. https://learn.microsoft.com/en-us/entra/identity-platform/scopes-oidc
13. https://practiceguides.chambers.com/practice-guides/life-sciences-pharma-ip-litigation-2025/australia/trends-and-developments
14. https://www.bu.edu/law/files/2017/10/The-Ways-Weve-Been-Measuring-Patent-Scope-Are-Wrong-How-to-Measure-and-Draw-Causal-Inferences-with-Patent-Scope.pdf
15. https://www.brmpatentattorneys.com.au/patent/
16. https://www.spruson.com/pharmaceutical-patent-term-extension-in-australia/
17. https://blog.patentology.com.au/2017/10/australian-patent-law-contains-includes.html
18. https://pubchem.ncbi.nlm.nih.gov/patent/US-8999313-B2
19. https://www.ipaustralia.gov.au/patents/search-existing-patents